GRI Bio (GRI) Expected to Post Quarterly Earnings on Thursday

GRI Bio (NASDAQ:GRI) is expected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect GRI Bio to announce earnings of ($1.20) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.

GRI Bio (NASDAQ:GRI) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.01). On average, analysts expect GRI Bio to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

GRI Bio Stock Up 29.4%

GRI opened at $2.20 on Wednesday. GRI Bio has a twelve month low of $1.36 and a twelve month high of $80.36. The company has a 50-day moving average price of $1.78 and a 200 day moving average price of $2.28. The company has a market cap of $3.89 million, a PE ratio of -0.03 and a beta of -1.21.

Wall Street Analyst Weigh In

Several research firms have commented on GRI. Ascendiant Capital Markets cut their price objective on GRI Bio from $40.00 to $32.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Weiss Ratings restated a “sell (e+)” rating on shares of GRI Bio in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, GRI Bio presently has a consensus rating of “Hold” and a consensus target price of $32.00.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.